Abstract
For several major cancers, drug selection already pivots on biomarker results (e.g., trastuzumab for breast cancer, and gefitinib and erlotinib for lung cancer). Fast-paced advances in genomic and proteomic laboratory technologies could enable the widespread use of molecular testing before therapy selection in any field of medicine. This article describes two potentially large obstructions to such innovation. First, laboratory tests have traditionally been commodities with low prices, prices that matched the resources required to operate the laboratory technology itself. Assuming that the marginal costs of molecular laboratory technology will fall, there will be a widening chasm between estimated test revenue and the costs of innovative and definitive clinical trials, and regulatory approval for new tests. Without corrective action, even cost-saving laboratory tests could be in shortfall, because they will not be created through upfront investment. Second, it is argued that while diagnostic tests, drugs and surgical procedures should meet a fundamental standard for payer coverage ('will health outcomes be improved?'), molecular diagnostics could require different analysis pathways than those that are used to evaluate interventi...Continue Reading
References
Oct 18, 2005·Perspectives in Biology and Medicine·Jason Grossman, Fiona J Mackenzie
Jul 28, 2006·PLoS Clinical Trials·Peter M Rothwell
Aug 4, 2007·American Journal of Preventive Medicine·Shawna L MercerDenise Dougherty
Dec 13, 2007·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Muin J KhouryLinda Bradley
Oct 15, 2008·Circulation·P Michael HoFrederick A Masoudi
Dec 23, 2008·Lancet·Michael Rawlins
Feb 11, 2009·Public Health Genomics·P A Deverka
Mar 14, 2009·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Mitchell I BurkenEric Seifter
Apr 21, 2009·International Journal of Epidemiology·O M DekkersJ P Vandenbroucke
May 8, 2009·The New England Journal of Medicine·Alan M Garber, Sean R Tunis
Jul 2, 2009·Annals of Internal Medicine·Bryan R LuceJ Sanford Schwartz
Sep 10, 2009·Journal of the National Cancer Institute·Salvatore SienaAlberto Bardelli
Oct 10, 2009·Journal of the National Cancer Institute·Richard M SimonDaniel F Hayes
Nov 17, 2009·Cancer Control : Journal of the Moffitt Cancer Center·Benjamin Djulbegovic
Dec 2, 2009·Nature Reviews. Drug Discovery·Michael Goodman
Jan 1, 2010·Journal of the National Cancer Institute·Garnet L AndersonNicole Urban
Apr 30, 2010·Genetics in Medicine : Official Journal of the American College of Medical Genetics·E Richard Gold, Julia Carbone
Citations
Dec 23, 2011·Personalized Medicine·Donna H OdiernaNinez A Ponce
Mar 1, 2011·Personalized Medicine·Laura Housman
Jan 16, 2014·International Journal of Health Care Quality Assurance·Anthony Woodhead